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Abstract 
Many healthcare systems globally provide publicly subsidised access to prescribed medicines. 
Decisions about which medicines to fund affect a range of stakeholders and it is not reasonable to 
expect that medicines funding decisions are supported by all stakeholder groups all the time. A more 
realistic aim may be for decisions to be understood and accepted as legitimate by stakeholders, 
however several shortcomings of existing processes make it difficult to achieve this aim. To date, the 
main strategy to address these shortcomings has been to increase stakeholder involvement in 
decision-making, either by eliciting stakeholder values or increasing stakeholder participation in 
decision-making. Despite these efforts, there is growing evidence that decision-makers are falling 
short when it comes to the perceived legitimacy of their resource allocation processes and decisions. 
As such, there is a pressing need for decision-makers to think seriously and creatively about ways to 
increase the legitimacy of their processes and to make them more acceptable to a wider range of 
stakeholders. In this article we summarise and critique existing literature on the legitimacy of public 
resource allocation processes, and make some practical suggestions for those who are concerned 
about this issue. 
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Pharmaceuticals are expensive and subsidy is required before most patients achieve access 
 
Pharmacotherapies play a vital role in the treatment of disease but they are also expensive, both in 
terms of overall and unit costs. It is not uncommon for new therapies (particularly biological agents 
and targeted therapies used to treat conditions such as cancer, hepatitis and autoimmune disease) 
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to cost upwards of $100,000 per patient for a year of treatment (1). Meanwhile, expenditure on 
prescribed pharmaceuticals accounted for US$263.3billion in the USA in 2012 (2), €190billion in the 
European Union in 2010 (3) and $10.1billion in Australia in 2013-14 (4); representing 1.6, 1.7 and 
0.7% of GDP, respectively. It is predicted that these costs will increase substantially in the near 
future (5), due to factors such as the development of new expensive targeted biological agents (6), 
the ageing population in many countries (7) and the emergence of new healthcare markets, 
particularly in the developing world (5).  
 
The high cost of many therapies means that, in practice, some form of subsidy is required before all 
but the wealthiest patients can access them. Many jurisdictions internationally have public 
mechanisms in place to provide subsidised access to prescribed medicines. Examples include 
national publically funded healthcare schemes such as the UK’s National Health Service (NHS), the 
United States Medicare and Medicaid programs (CMS) and Australia’s Pharmaceutical Benefits 
Scheme (PBS), as well as publicly funded hospital drug and therapeutics committees (8). Low and 
middle-income countries are also increasingly focused on finding ways to provide public access to 
“essential” medicines, some of which are very expensive (9-11). 
 
Medicines funding decisions affect a range of stakeholders, all of whom make different “claims” 
for funding of medicines 
 
Decisions about subsidising expensive prescribed medicines in public healthcare systems occur in the 
context of escalating healthcare costs and budget constraints. Healthcare payers must therefore 
make difficult choices as to which therapies are subsidised, and inevitably some patients will miss 
out on subsidy for treatment that they need or want.  
In this context, different stakeholder groups tend to make different kinds of “claims” for funding of 
medicines. Patients, patient advocates and clinicians generally emphasise the importance of timely 
access to effective medicines at a price consumers can afford, the need for equity between different 
patient groups and the need to “rescue” desperately ill patients. These views emerge regularly in the 
media when a decision is made to refuse public funding for particular therapies (12-15). 
Pharmaceutical companies typically focus on the need for public payers to fund more medicines and 
reward companies for the costs associated with drug development; this is illustrated in a recent 
report commissioned by Medicines Australia (Australia’s pharmaceutical industry representative 
body), entitled “Access to Cancer Medicines in Australia” (6). Public payers and those advising them 
acknowledge the importance of factors such as equity and rewarding and encouraging drug 
development, but emphasise that effectiveness and cost-effectiveness of medicines must be 
demonstrated before they can be subsidised.  This is evident in the guidelines of health technology 
assessment agencies (such as Australia’s Pharmaceutical Benefits Advisory Committee’s (PBAC) (16), 
the UK’s National Institute for Health and Clinical Excellence (NICE) (17) and the Canadian Agency for 
Drugs and Technology in Health (CADTH) (18)) that provide advice to payers.  
 
Stakeholder claims are difficult to reconcile and it is nearly impossible to make decisions that all 
stakeholders agree with  
 
The tensions between these conflicting stakeholder positions mean that it is nearly impossible to 
make decisions that all stakeholders will agree with all of the time. Therefore, a more realistic aim 
may be to make funding decisions that stakeholders can understand and accept as legitimate. In this 
context, “legitimacy” refers to the degree to which a decision or decision-making process is seen to 
be in accordance with established or accepted patterns and standards and, therefore, to be 
“acceptable”.  
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Perceived legitimacy of public resource allocation processes is important because, without it, 
attempts will inevitably be made to “work around” the decision-making process, potentially 
undermining it (19). An example of this is the “Herceptin Program” in Australia (20). This was 
established as a separate funding mechanism after the government’s advisory group (the 
Pharmaceutical Benefits Advisory Committee) did not recommended public funding of trastuzumab 
(Herceptin) for metastatic disease on the Pharmaceutical Benefits Scheme, as it was not deemed to 
be cost-effective. Other examples include England’s “cancer drugs fund”, which was established in 
2011 to provide access to cancer medications that are not available through the National Health 
Service (21), and the increased demands that are often placed on hospital drug and therapeutics 
committees by patients who cannot obtain subsidy for therapies through publicly funded healthcare 
schemes (8). Even if people do not attempt to “work around” systems they perceive to be 
illegitimate, legitimacy in decision-making is still important, as it is an essential feature of liberal 
democracy. Officials are elected to make decisions on behalf of the population and voters expect 
these decisions to be made in a manner that considers their views, respects community values and is 
able to balance competing considerations (22).  
 
Legitimacy of decision-making processes for funding of medicines has been examined and some 
shortcomings of existing processes identified  
 
Researchers and policymakers have paid significant attention to the process of healthcare resource 
allocation. To date, most work in this area has involved characterising and describing existing 
processes to determine how decisions about the funding of medicines are made (examples include 
work by Gallego et al. (23, 24) and Martin et al. (25-28) examining hospital drug and therapeutics 
committees or Mitton et al. (19) examining centralised decision-making processes in Australia, 
Canada, the UK and Israel). Other work has focussed specifically on the perceived legitimacy of these 
processes and several weaknesses of current processes have been identified.  
 
Firstly, concerns about transparency have been raised. Examinations of hospital decision-making 
committees in Australia (23, 26, 27), for example, have found that limited information about the 
decisions of these bodies is made available to hospital staff, patients or the broader community. 
Meanwhile, participants in an interview-based study by Mitton (19) examining the fairness of 
centralised decision-making processes in Australia, New Zealand, Canada and the UK acknowledged 
recent attempts to increase the transparency of funding processes by posting final decisions on the 
agency websites; however, they noted that only limited information is provided and questioned the 
adequacy of this approach.  
 
Second, those concerned about legitimacy have raised concerns (19, 23, 27) that the full range of 
interests is not represented in resource allocation processes. Limited opportunities for stakeholder 
participation in some processes have been noted, in particular involvement of patients and 
members of the broader community in hospital decision-making committees. For example, a review 
of empirical research into decision-making in priority-setting for medicines in industrialised countries 
(29) found that experts such as physicians and pharmacists were the most influential stakeholders in 
hospital decision-making processes; lay people were rarely involved. Similarly, lack of community 
engagement has been emphasised in a number of case studies examining hospital decision-making 
committees in Australia (23) and Canada (25-28, 30).  
 
Decision-making bodies are making efforts to increase the legitimacy of their processes 
 
A number of strategies have been identified that may increase the legitimacy of medicines funding 
decisions. For the most part, these have focused on ways of increasing stakeholder participation in 
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decision-making, as this is thought to increase transparency (19, 23, 31, 32) and provide decision-
makers with unique patient knowledge about treatments (33).  
 
Currently there are two main approaches suggested for increasing public participation: eliciting 
stakeholder views for incorporation in decision-making and increasing stakeholder involvement in 
decision-making processes. Researchers have suggested focus groups, citizens juries (34), discrete 
choice experiments (35) and surveys (36, 37) as methods that could be used to elicit stakeholder 
opinions for incorporation into decision-making. For example, Gallego et al. (37) conducted a survey 
of 200 people in the Sydney metropolitan area to explore what members of the general public 
considered to be important criteria for resource allocation. Linley and Hughes (35) conducted a 
larger study of 4,118 members of the general public in the UK using a discrete choice experiment to 
explore societal preferences for NHS resource allocation. Menon and Stafinski (34) used a citizens 
jury composed of 16 members of the general public in Alberta, Canada to elicit preferred 
prioritisation criteria. Meanwhile, a review of public participation in decision-making by Menon et al. 
(38) identified a variety of methods that can be used to increase stakeholder involvement in 
decision-making. These include involving the public in decisions about which technologies to 
appraise, including stakeholders on decision-making committees, providing stakeholders with 
opportunities to make submissions to decision-making bodies and to appeal the decisions of health 
technology assessment bodies, and allowing stakeholders to review the guidelines and summary 
documents produced by health technology assessment bodies.  
 
While the ideal approach to increasing public participation is not yet clear, a number of decision-
making bodies have taken up these strategies. In the UK, the NICE Citizens’ Council is one public 
consultation mechanism that has been used to elicit community values for incorporation into 
decision-making (39, 40). This consists of 30 members of the general public that meet once a year to 
discuss issues identified as important to NICE decision-making. Council recommendations and 
conclusions are collated into a report, which is then considered in NICE appraisals. NICE also has a 
“Patient and Public Involvement Programme”, which seeks to engage patients, carers and the public 
in the development of NICE guidance (41); stakeholders can also comment and provide evidence at 
various stages of guideline scoping and development (17). Meanwhile, the Canadian Agency for 
Drugs and Technologies in Health (CADTH) has a system for patient group input to its Common Drug 
Review (CDR) process (42).  
 
The success of efforts to increase legitimacy has been limited  
 
Despite these efforts to engage the public, and integrate their values into decision-making, there is 
evidence of persistent problems with the perceived legitimacy of decision-making processes for the 
funding of medicines. Media articles continue to detail patients pleading for and being given ad hoc 
compassionate access to therapies (described in studies by MacKenzie et al. (12) and Robertson et 
al. (13) examining media coverage of medicines funding decisions). There are also heated debates 
currently occurring in a number of jurisdictions about the use of “cancer drugs funds”, with calls for 
Australia to establish such a fund (43) at the same time that the future of the English fund is 
uncertain (44). Thus, while existing work in this area provides a useful starting point, there is a need 
for agencies making decisions about the funding of medicines (or those planning to establish and run 
such agencies in the future) to consider new ways to increase the perceived legitimacy of their 
processes, taking into account a range of stakeholder perspectives.  
 
A number of processes and tools have been identified that could be used to enhance the legitimacy 
of decision-making. One of these that we believe holds great promise is the 6-STEPPs tool (45, 46). 
This consists of six modules: decision clarification, criteria filtering (including aspects like strength of 
evidence, outcome benefit importance and regulatory status), clinical evaluation, cost modeling, 
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data integration and values clarification, and process evaluation. The tool was designed to overcome 
many of the weaknesses of existing processes and, as such, has an emphasis on increasing 
stakeholder involvement in decision-making and includes a template that forms a record that can be 
used to ensure accountability. It has undergone pilot testing with a number of clinical groups in 
Alberta, Canada, where it has been received favourably and has continued to be used by participants 
after the pilot-testing process had occurred. Although further evaluation is needed to determine the 
effect that the use of this tool has on the acceptability of decisions to other stakeholders, it could 
play a useful role in increasing the legitimacy of decisions about the funding of medicines.  
 
Conclusions  
Different stakeholders make different, and often incompatible, claims for the public funding of 
medicines. Overall, there are two competing sets of stakeholder claims- those of patients, 
manufacturers and physicians, who advocate for increased access to medicines, with reduced time 
to access and at a price that patients can afford, and those of public payers, who focus on achieving 
equitable access to healthcare within a fixed budget. The difficulties in reconciling these claims, and 
therefore in making decisions that all stakeholders agree with, means that a more appropriate aim 
may be for decisions that stakeholders can understand and accept as legitimate. There is evidence 
that public decision-makers internationally are alert to the importance of perceived legitimacy, and 
are attempting to increase the legitimacy of their processes, primarily by increasing stakeholder 
participation in decision-making. Although these efforts—and the body of research that has 
accompanied them—provide a useful starting point, continued concerns about legitimacy 
underscore the need for those making decisions about the funding of medicines to seriously 
consider the perceived legitimacy of their processes from the perspective of a number of 
stakeholders and to make efforts to increase this. The use of tools such as 6-STEPPS to aid decision-
making are one way that agencies could increase the legitimacy of their processes and make them 
more acceptable to a wider range of stakeholders.  
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